Discovery of Dual VEGFR-2 and Tubulin Inhibitors with in Vivo Efficacy

Discovery of Dual VEGFR-2 and Tubulin Inhibitors with in Vivo Efficacy Discovery of Antitubulin Agents with Antiangiogenic Activity as Single Entities with Multitarget Chemotherapy Potential Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy